THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION


Associated tags: Harbor–UCLA Medical Center, Pharmaceutical industry, Patient, Medicine, Doctor of Philosophy, UCLA, Research, Infection, Division, David Geffen School of Medicine at UCLA, TLI, Nursing

Locations: LOS ANGELES, TORRANCE, CA, CALIFORNIA

The Lundquist Institute Receives $2.6 Million Grant from U.S. Army Medical Research Acquisition Activity to Develop Wearable Biosensors

Retrieved on: 
Thursday, April 25, 2024
UCLA, Mortality, Patient, Lower respiratory tract infection, Blood, Health, CRP, Death, Partnership, Doctor of Philosophy, Research, COPD, TLI, Electronics, Conditional sentence, AECOPD, Hospital, Perspiration, Infection, Disease, Chronic obstructive pulmonary disease, Pharmaceutical industry

Torrance, California, April 24, 2024 (GLOBE NEWSWIRE) -- The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234.

Key Points: 
  • Torrance, California, April 24, 2024 (GLOBE NEWSWIRE) -- The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234.
  • The research project is led by Dr. Harry Rossiter, an investigator at TLI and Professor at the David Geffen School of Medicine at UCLA.
  • The project aims to develop wearable multiplex biosensors to monitor exacerbation risk in chronic obstructive pulmonary disease (COPD).
  • COPD affects approximately 16 million Americans and is the third leading cause of death globally.

Lundquist Investigator Dr. Yoshihara Awarded $3 Million NIH R01 Grant for Diabetes Stem Cell Therapy Research

Retrieved on: 
Monday, April 1, 2024
TLI, Diabetes, Immunosuppression, Type 1, Research, Kidney, Hope, Doctor of Philosophy, NIH, Type 1 diabetes, NIDDK, Bangladesh Technical Education Board, UCLA, Digestive, Health, Cell, Organoid, Type 2, Medical device

This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.

Key Points: 
  • This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.
  • Insulin-dependent diabetes, including autoimmune Type 1 and stress-induced Type 2, presents a significant health burden, often necessitating lifelong insulin therapy and glucose monitoring.
  • Dr. Yoshihara's research focuses on the potential of human pluripotent stem cells (hPSCs) to create functional islet cells.
  • “Despite significant progress in stem cell-derived mini-organ technologies, we are still challenged by their functional immaturity and variability,” said Dr. Yoshihara.

TLI Investigator Dr. Nicholas Jenzjowsky Receives NIH/NIAID Grant to Investigate the Neural Regulation of Asthma

Retrieved on: 
Wednesday, March 20, 2024
TLI, Asthma, Research, Hope, Doctor of Philosophy, Allergy, Neuron, Immunoglobulin E, Infection, Pharmaceutical industry

The grant will fund the innovative project "Asthmatic inflammation requires neuronal upregulation of B-cells," which commenced this month and will run until January 2025.

Key Points: 
  • The grant will fund the innovative project "Asthmatic inflammation requires neuronal upregulation of B-cells," which commenced this month and will run until January 2025.
  • This groundbreaking research aims to delve into the complexities of asthma and its symptoms, a major global health concern that requires a deeper understanding of its underlying mechanisms.
  • The innovative nature of this project underscores TLI's commitment to cutting-edge science and the potential impact of the research.
  • It aims to uncover potential drug targets and inform new strategies to mitigate the growing problem of allergic asthma.

TLI Investigator Dr. Wei Yan Named Editor-in-Chief of the Andrology Journal

Retrieved on: 
Monday, March 18, 2024
Reproduction, Lundquist, Managing editor, Infertility, SSR, Male, Social media, Research, Fertility, Doctor of Philosophy, MD, Biology of Reproduction, Society, ELife, Biology, Reproductive medicine, UCLA, Management

Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.

Key Points: 
  • Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.
  • With over 160 peer-reviewed publications and numerous awards, Dr. Yan is a committed researcher and educator.
  • Dr. Yan's vision for Andrology is to enhance its global influence and implement innovative strategies.
  • His plans include prioritizing cutting-edge reviews, rewarding high-quality contributions, and fostering the next generation of researchers through the Trainee Reviewer Program.

Lundquist Institute Investigator Dr. Loren Miller to Receive 2024 Top Ten Clinical Research Achievement Award from the Clinical Research Forum

Retrieved on: 
Thursday, February 15, 2024
Infection, Human services, Chlorhexidine, Paris Las Vegas, University of California, Irvine, Nursing, TLI, Harbor–UCLA Medical Center, Physiology, Agency, Conference, Disease, Interim, Health, Tufts University, University, UC, MPH, Clinical trial, Diagnosis, Science, UCLA, Nose, Pharmaceutical industry

Los Angeles, California, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) is pleased to announce that Lundquist Investigator Loren Miller, MD, MPH will be honored with a 2024 Top Ten Clinical Research Achievement Award

Key Points: 
  • Los Angeles, California, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) is pleased to announce that Lundquist Investigator Loren Miller, MD, MPH will be honored with a 2024 Top Ten Clinical Research Achievement Award
    by the Clinical Research Forum (CR Forum) at a ceremony in Las Vegas, NV on April 2, 2024.
  • The Top 10 Clinical Research Achievement Awards honor groundbreaking achievements in clinical research nationwide.
  • The award recognizes the Protect Trial, a clinical trial jointly led by Dr. Miller and senior investigator Susan Huang, MD, MPH, Chancellor’s Professor at the University of California, Irvine.
  • “I am pleased to congratulate Dr. Loren Miller on receiving this prestigious award from the Clinical Research Forum,” said Dr. Marianne Gausche-Hill, Interim President and CEO of The Lundquist Institute.

CORRECTION: Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New England Journal of Medicine

Retrieved on: 
Wednesday, October 11, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, University, CDC, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Nursing home, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

The findings were published on October 10, 2023, in the New England Journal of Medicine.

Key Points: 
  • The findings were published on October 10, 2023, in the New England Journal of Medicine.
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • “Nursing Home Decolonization for Infection and Hospitalization Prevention” published in the New England Journal of Medicine on October 10, 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2215254?query=featured_home

Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New English Journal of Medicine

Retrieved on: 
Tuesday, October 10, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, CDC, University, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

“The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.

Key Points: 
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • Each year, 3 million healthcare-associated infections (HAIs) such as methicillin-resistant Staphylococcus aureus (MRSA), bloodstream and urinary tract infections occur in U.S. nursing homes.
  • The findings add to a growing body of Dr. Miller’s research that has been funded by NIH, AHRQ, and other federal sources.

Lundquist Investigator Dr. Harry Rossiter Awarded $3.8 Million NIH Grant To Develop the Next-Generation Cardiopulmonary Exercise Test

Retrieved on: 
Wednesday, September 20, 2023
Exercise, Heart, David Geffen School of Medicine at UCLA, TLI, R01, Research, Doctor of Philosophy, Bangladesh Technical Education Board, Athlete, Gold, Patient, 4-HO-McPeT, CPET, UCLA, Harbor–UCLA Medical Center, NIH, Disease, Medical device, Medicine

The R01 is the most prestigious and competitive NIH grant (only 10% are funded) awarded to biomedical researchers.

Key Points: 
  • The R01 is the most prestigious and competitive NIH grant (only 10% are funded) awarded to biomedical researchers.
  • Dr. Rossiter’s research team at TLI has developed the next generation of the cardiopulmonary exercise test; the standard clinical test to investigate exercise intolerance.
  • “This research builds on what Lundquist Institute investigators developed fifty years ago,” said David I. Meyer, TLI President and CEO.
  • “This next-generation CPET being developed by Dr. Rossiter and his team will become the new gold standard for clinical investigation of exercise intolerance.”

Lundquist Principal Investigator Dr. Michael Yeaman Awarded $11.5 Million NIAID/HHS Grant for Innovative Research To Understand and Solve Persistent Bloodstream Infections

Retrieved on: 
Tuesday, August 15, 2023
Vaccine, Infection, DNA, Duke University Hospital, Centers for Disease Control and Prevention, Genetics, TLI, Epigenomics, Public, National Institute of Allergy and Infectious Diseases, MRSA, Immunity, Biomedical Research, Hope, Research, Antimalarial medication, Staphylococcus, Doctor of Philosophy, Bangladesh Technical Education Board, CDC, Harbor–UCLA Medical Center, Molecular medicine, Principal investigator, Division, Risk, Immune system, Nightfall and Other Stories, Biological engineering, NIAID, Principal, UCLA, United States Department of Health and Human Services, NIH, Bloodstream infections, Pharmaceutical industry, Health, Medicine, U19

In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.

Key Points: 
  • In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.
  • The focus of this U19 is on infections caused by the bacterium Staphylococcus, including methicillin-resistant S. aureus (MRSA) and the invasive fungus, Candida.
  • Dr. Yeaman and team made previous discoveries that laid essential groundwork for this project to find new ways to prevent and treat persistent bloodstream infections.
  • “We will use state-of-the-art technologies in synergistic research to understand human-pathogen interactions driving persistence,” said Dr. Yeaman.

The Lundquist Institute Receives Gift from the Samberg Foundation to Study the Use of Psilocybin in Alleviating Demoralization and Psychological Distress in Palliative Care

Retrieved on: 
Monday, July 24, 2023
Psilocybin, Lundquist, David Geffen School of Medicine at UCLA, Depression, Face, TLI, Anxiety, Cancer, Quality of life, Death anxiety, Terminal illness, Research, Doctor of Philosophy, Person, Pain, Medicine, CQD, MD, Patient, Grammatical mood, Palliative care, UCLA, FDA, MDMA, Joe, Safety, Pharmaceutical industry, Nursing, New York University

Los Angeles, California, July 24, 2023 (GLOBE NEWSWIRE) -- The Joe & Sandy Samberg Foundation has made a gift of $300,000 to The Lundquist Institute to study the use of psilocybin in alleviating demoralization and the psychological distress associated with life-threatening illness in palliative care.

Key Points: 
  • Los Angeles, California, July 24, 2023 (GLOBE NEWSWIRE) -- The Joe & Sandy Samberg Foundation has made a gift of $300,000 to The Lundquist Institute to study the use of psilocybin in alleviating demoralization and the psychological distress associated with life-threatening illness in palliative care.
  • The gift will facilitate an FDA-approved multi-site clinical trial.
  • Our earlier research with psilocybin suggests that improved mood and lessening of death anxiety and demoralization can occur, even in the context of extreme and dire health circumstances.
  • We are very thankful to the Samberg Foundation for this gift, which allows us to continue to explore this promising therapy in FDA-clinical trials.”